Donald P. Beeman; Chief Executive Officer & Chairman of the Board. Mr. Beeman has over 28 years of executive experience in the pharmaceutical and vaccine industry. Previously, Mr. Beeman was the Vice President for Merck's Vaccine Division. Mr. Beeman established a strong leadership reputation at Merck, having held executive positions in the Pharmaceutical and Marketing Divisions in both the United States and Australia. Before joining LigoCyte, Mr. Beeman served as President and Co-Founder of Topaz Pharmaceuticals, LLC. At LigoCyte, Mr. Beeman's experience and leadership skills direct resources towards the successful commercialization of the company's technology. don.beeman@ligocyte.com

Robert R. Goodwin, Ph.D.; President & Chief Operating Officer. Dr. Goodwin became President at LigoCyte in November of 2005. Dr. Goodwin joined the company in 2000 as the Director of Business Development and was later promoted to Executive Vice President & Chief Operating Officer. Dr. Goodwin has degrees in Bioengineering from UCLA and the University of Utah, and has extensive experience in intellectual property licensing. Formerly the director of technology transfer at the University of Rochester (Rochester, NY), he has also held business development and research positions in the medical device industry. At LigoCyte, Dr. Goodwin's experience and educational background are applied to overseeing company operations and expanding the company's commercial opportunities.
 robert.goodwin@ligocyte.com

Robert F. Bargatze, Ph.D.; Executive Vice President, Chief Scientific Officer. Dr. Bargatze manages LigoCyte's research programs with a focus on product development. He has 29 years of experience in leading immunological research projects to define the role of selectins, integrins, and chemokines in white blood cell recruitment, and has published extensively on endothelial bioadhesion and signaling. Dr. Bargatze was a key member of the team at Stanford University that pioneered bioadhesion research. robert.bargatze@ligocyte.com

Charles E. Richardson, Ph.D.;  Executive Vice President, Research and Development. Dr. Richardson directs LigoCyte’s pre-clinical development activities in support of clinical trials and regulatory filings. His expertise in guiding both therapeutics and vaccines through development into clinical trials comes from his 15 years of senior management experience working for Corixa Corporation and Ribi ImmunoChem Research, Inc. Dr. Richardson has authored numerous peer-reviewed manuscripts and is an inventor on four U.S. patents. charles.richardson@ligocyte.com

Larry W. Mikkola, MBA, CPA; Controller, Director of Finance. A certified public accountant, Mr. Mikkola manages LigoCyte’s finance and accounting functions. He has finance and accounting experience with publicly traded companies. Prior to joining LigoCyte Mr. Mikkola worked for KPMG and then was the Controller and Assistant Treasurer for Westmoreland Coal Company. larry.mikkola@ligocyte.com

The members of our Board of Directors are distinguished scientists and businessmen with the executive leadership experience and financial acumen necessary to guide LigoCyte’s success.

Mark McDade, Chief Executive Officer, Protein Design Labs

Donald deBethizy, Ph.D., Chief Executive Officer & President, Targacept, Inc.

William G. Little, former Chairman & retired Chief Executive Officer, West Pharmaceutical Services

Robert F. Bargatze, Ph.D., CSO & Founder, LigoCyte Pharmaceuticals, Inc.

John W. Jutila, Ph.D., retired VP, Research, Montana State University & Founder, LigoCyte

Jon Marchi, Chairman, Glacier Venture Fund & The Development Corporation of Montana

John Tomlin, Founding Partmer of  The Vista Venture Group

Scott Warwood, Montana General Manager, Johnson Controls, Inc.

Our Scientific Advisory Board members are internationally recognized researchers. Their collective expertise enhances the focus of our product development efforts.

Harry B. Greenberg, M.D., Senior Associate Dean for Research and Professor of Medicine; Microbiology and Immunology, Stanford University School of Medicine

Marian Neutra, Ph.D., E. & M. Gordon Distinguished Professor of Pediatrics, Children’s Hospital Harvard University

Russ Middaugh, Ph.D., A. & T. Higuichi Distinguished Professor of Pharmaceutical Chemistry, University of Kansas

Bryan Finkle, Ph.D., Vice President (retired) for Development and Regulatory Affairs, Canji, Inc. and Director of Pharmacology (retired), Genentech, Inc.

John W. Jutila, Ph.D., retired VP, Research, Montana State University & Founder, LigoCyte